Navigation Links
Four deaths cause halt of flu vaccination in Israel

A spokeswoman reported that Israeli Health Ministry had suspended flu vaccine administration on Sunday following the deaths of 3 people who were inoculated. According to// the Israeli media, the fourth death was reported later.

'The ministry is investigating whether the deaths are connected to the vaccines,' said Inbal Jacobs, a ministry spokeswoman. According to the Israel Radio, the 3 deaths reported in the last few days were from a southern Israeli town of Kiryat Gat. All the 3 of them were already suffering from diseases.

At a news conference, Heath Minister Yaakov Ben-Yizri said, 'They were suffering from various illnesses, so that the team that has checked it so far has not found any connection between this tragedy and the vaccinations.' The fourth person, who died on Sunday after receiving a flu shot, belonged to a different region of Israel and had been suffering from a chronic illness.

The report says that more than 1,40,000 Israelis, at high or very high risk of complications from the flu were vaccinated in the last few weeks. The French pharmaceutical company Sanofi-Aventis manufactured the vaccine and the Israeli company Medici distributed it. The company has been asked by the Health Ministry to examine its laboratories, reports Israel's Army Radio.

According to Israel's Channel 10 TV report of a Health Ministry meeting, the direct association of the deaths with the vaccines is unlikely and vaccination may be resumed from today.
GYT
'"/>




Page: 1

Related medicine news :

1. Nearly all asthma deaths preventable
2. Increase in tobacco deaths
3. Aspirin reduces deaths
4. Immunisation to prevent cot deaths
5. Drop in global deaths from measles
6. Drop in Worldwide Measles deaths by 40%
7. Health care errors blamed for deaths
8. Serevent, to be examined by experts due to deaths associated with its use
9. WHO reports 36 million deaths world wide due to chronic diseases
10. Annual PSA screening reduces risk of prostate cancer deaths
11. Panic and probe due to mysterious deaths
Post Your Comments:
Other Medicine News:Health News:Reed Smith to Merge with Richards Butler Hong Kong 2Health News:Reed Smith to Merge with Richards Butler Hong Kong 3Health News:Reed Smith to Merge with Richards Butler Hong Kong 4Health News:The politics of the playground: lack of athletic skill often means loneliness and peer rejection 2Health News:MDS Nordion signs 17-year contract with Rosenergoatom 2Health News:UP Repeats NCQA Certification in Utilization Management 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 3Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 2Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 3Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 4Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 5Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 6Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 7Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 8Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 9Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 10Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 11Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 12Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 13Health News:Kensey Nash Reports First Quarter Fiscal Year 2008 Results 14
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 1Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 2Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 3New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 1New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 2New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 3Viewers Beware Report by Watchdog Group Exposes Conservative Group Behind Anti Healthcare Ads Running in Montana 47530 1Viewers Beware Report by Watchdog Group Exposes Conservative Group Behind Anti Healthcare Ads Running in Montana 47530 2